Back to the Top
Is anyone aware what Phase 2 metabolism A549 lung cancer cells are
capable of? Can they glucuronidate or sulfate drugs? I can't really
find anything on this doing a quick Medline search. If you know of a
reference that would be fantastic.
Thank you in advance,
Peter L. Bonate, PhD, FCP
4545 Horizon Hill Blvd
San Antonio, TX 78229
Back to the Top
The following message was posted to: PharmPK
In our hands A549 cells are metabolically very capable cells. However, I
have no direct information on Phase 2 metabolism in this cell line but
being a lung cell I'd assume they would express 'reasonable' levels of
conjugating enzymes. This cell line is also in the NCI cell line panel
and more information may be gleaned from NCI's Website. The following
references (ex Medline) may be useful:
Castell JV. Donato MT. Gomez-Lechon MJ. Metabolism and bioactivation of
toxicants in the lung. The in vitro cellular approach. Experimental &
Toxicologic Pathology. 57 Suppl 1:189-204, 2005 Jul.
Munzel PA. Lehmkoster T. Bruck M. Ritter JK. Bock KW. Aryl hydrocarbon
receptor-inducible or constitutive expression of human UDP
glucuronosyltransferase UGT1A6. Archives of Biochemistry & Biophysics.
350(1):72-8, 1998 Feb 1.
Munzel PA. Bookjans G. Mehner G. Lehmkoster T. Bock KW. Tissue-specific
2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible expression of human
UDP-glucuronosyltransferase UGT1A6. Archives of Biochemistry &
Biophysics. 335(1):205-10, 1996 Nov 1.
Wiebel FJ. Kiefer F. Krupski G. Schuller HM. Expression of glutathione
S-transferase and phenol sulfotransferase, but not of
UDP-glucuronosyltransferase, in the human lung tumor cell lines NCI-H322
and NCI-H358. Biochemical Pharmacology. 35(8):1337-43, 1986 Apr 15.
Frederik B. Pruijn PhD MSc (Senior Research Fellow)
Experimental Oncology Group
Auckland Cancer Society Research Centre
Faculty of Medical and Health Sciences
The University of Auckland
Private Bag 92019
Phone: +64-9-3737 599 x86939 or x86090
Fax: +64-9-3737 571
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (email@example.com)